The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Ludvig Svensson, Erik Penser Bank, Tel: +46 8 463 80 00. Erik Penser Bank equity research

Annual Report

  November 29, 2022

Company Presentation

 July 21, 2023
  Quarterly Report 3 22/23, June 28, 2023
We continue to progress our precision medicine Phase 3 trial DIAGNODE-3 with the antigen-specific immunotherapy Diamyd® and I am very happy to announce that all eight European countries where DIAGNODE-3 is ongoing have randomized patients to the trial and we hope to start the trial in the US shortly.

In light of the recent approval of Teplizumab in the US, and the subsequent acquisition of...
I am very happy to announce that all eight European countries where DIAGNODE-3 is ongoing have randomized patients to the trial and we hope to start the trial in the US shortly.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
123
October 2 − October 6, 2023
EASD 2023
October 9, 2023
Aktiedagen i Lund
October 10, 2023
Extra General Meeting
October 11, 2023
Year-end report
Year-end report 2022/2023
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of July 31, 2023

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 10 738 910 12.52 9.87
Lindkvist, Bertil 7 700 000 8.98 7.08
Nordnet Pension 3 568 385 4.16 3.28
Essen-Möller, Anders * 556 223 2 813 040 3.93 7.70
Essen-Möller, Maria-Teresa 400 000 963 998 1.59 4.56
Konstruktions o Försäljningsaktiebolag 906 250 1.06 0.83
Essen-Möller, Jon 400 000 466 780 1.01 4.11
Esssen-Möller, Martin 400 000 298 513 0.81 3.95
Hillborg, Erika 400 000 283 287 0.80 3.94
Essenshaw, My 400 000 181 002 0.68 3.84
Remaining shareholders 55 305 926 64.47 50.84
Total 2 556 223 83 226 091 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS